Summary
Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.
In a closely watched competition among KRAS inhibitors, Amgen leads the pack with a randomized trial win in lung cancer. Now, the California drugmaker is giving a first look at the detailed data that could set the bar for all others to come, including Mirati Therapeutics, Roche and Novartis.
Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer, according to an abstract released at the European Society for Medical Oncology congress 2022. Lumakras is currently the only FDA-approved. KRAS inhibitor.
At one year, 24.8% of Lumakras takers were alive and did not show any disease worsening, versus 10.1% for docetaxel.
But when it comes to the exact time patients went without disease progression, Lumakras’ performance looks relatively weak. Lumakras only added an extra 1.1 months to patients’ progression-free survival time to a median 5.6 months. That came below the 6.3 months Lumakras had shown in the phase 1/2 CodeBreaK 100 trial that earned its landmark FDA accelerated approval last year. Based on historical data, industry watchers were largely expecting to see a two-month difference between the two treatment arms.
